Clinical trial
A Phase 2, Randomized, Placebo-controlled, 12-week, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Chinese Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
NCT06812754 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-controlled, 12-week, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Chinese Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 10, 2025
- Completion date
- March 5, 2026
- Enrollment
- 150 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.